TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Oblique Therapeutics AB (publ)
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 (consolidated) |
| Turnover |
506
|
0
|
0 |
| Financial expenses |
67
|
61
|
1,924 |
| Earnings before taxes |
-30,265
|
-62,736
|
-50,651 |
| EBITDA |
-29,404
|
-38,257
|
-45,622 |
| Total assets |
17,680
|
18,803
|
17,193 |
| Current assets |
16,073
|
16,380
|
7,669 |
| Current liabilities |
5,243
|
6,202
|
10,652 |
| Equity capital |
11,560
|
11,740
|
3,181 |
| - share capital |
2,354
|
1,850
|
718 |
| Employees (average) |
10
|
18
|
18 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 (consolidated) |
| Solvency |
65.4%
|
62.4%
|
18.5% |
| Turnover per employee |
51
|
0
|
0 |
| Profit as a percentage of turnover | -5981.2% | ||
| Return on assets (ROA) |
-170.8%
|
-333.3%
|
-283.4% |
| Current ratio |
306.6%
|
264.1%
|
72.0% |
| Return on equity (ROE) |
-261.8%
|
-534.4%
|
-1592.3% |
| Change turnover |
506
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
-8
|
0
|
2 |
| Chg. No. of employees % | -44% | 13% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.